bioRxivCancer BiologyPreprint
CDK4 as a phytochemical based anticancer drug target
R. K. Chando, N. Hussain, M. Islam Rana, S. Sayed, S. Alam, T. Ahmed Fakir, S. Sharma, A. Rahman Tanu, F. Mobin, E. Hoque Apu, M. K. Hasan, M. A. Sayed, M. A. Ashraf
Abstract
Success story of plant-based medicine had been overlooked during the advent of modern pharmaceutical industry. Despite the negligence of the multimillion-dollar drug industry, people entirely rely on medicinal plants in some part of the world. In this study, we have emphasized on going back to those traditional medicinal practices to figure out their underlying mechanism to move forward on phytochemical based drug development. We screened Medicinal Plant Database Bangladesh 1.0 (MPDB1.0) and on-going extension, MPDB2.0, of that database to find traditionally used medicinal plants and their active compounds. Here, Mangiferin, extracted from Mangifera indica, have been demonstrated to interact with cell cycle regulator Cyclin-dependent Kinase 4 (CDK4). CDK4 is differentially expressed during Glioblastoma multiforme (GBM), Brain Lower Grade Glioma (LGG), and Sarcoma (SARC). Expression of CDK4 is interlinked to the patients survival rate and its consistent expression throughout different stages have provided the advantage to use it as diagnostic tool and drug target. Altogether, this study demonstrated that simple mango tree extracted active compounds, mangiferin, can work as potential anticancer drug and leveraging the recent advancement of sequencing and gene expression data can accelerate the phytochemical based drug discovery process.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy
María Fuentes-Baile, José Antonio Encinar, … Miguel Saceda·bioRxiv·Sep 22, 2026
- Discovery of medicinal herbal compounds with potential anti-cancer activities against microtubule affinity-regulating kinase(MARK4) in cancer therapy
Nayana Narayanan, K.C Sivakumar·bioRxiv·May 30, 2023
- Gene Expression Mediated Antiproliferative Potential and Safety of Selected Medicinal Plants Against Cancerous and Normal Cells
R. W. MBUGUA, P. G. Mwitari, … C. M. Ngule·bioRxiv·Mar 16, 2019
- Analysis of Plant-derived Phytochemicals as Anti-cancer Agents Targeting Cyclin Dependent Kinase-2, Human Topoisomerase IIa and Vascular Endothelial Growth Factor Receptor-2
Bishajit Sarkar, Md. Asad Ullah, … Yusha Araf·Journal of Receptors and Signal TransductionPeer-reviewed·Aug 13, 2020
- Structure-based Design of CDC42 Effector Interaction Inhibitors For the Treatment of Cancer
Sohail Jahid, Jose A. Ortega, … Anand K. Ganesan·Cell ReportsPeer-reviewed·Apr 1, 2022
- IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics
Karthikeyan Mohanraj, Bagavathy Shanmugam Karthikeyan, … Areejit Samal·Scientific ReportsPeer-reviewed·Mar 6, 2018